Overview
PTD-DBM is a synthetic peptide with the CAS number 1609454-11-6, designed to interfere with a specific protein-protein interaction involving CXXC5, a zinc finger protein that acts as a negative regulator of the Wnt/β-catenin signaling pathway. It works by mimicking a region of the Dishevelled protein, allowing it to competitively block CXXC5 from suppressing Wnt signaling activity. This makes PTD-DBM a research tool of interest in the category of cell-signaling modulatory peptides, particularly in studies related to tissue regeneration and follicle biology. It has been investigated in preclinical research contexts exploring wound healing processes and the mechanisms underlying hair follicle cycling and androgenetic alopecia. PTD-DBM is intended strictly for laboratory research purposes and is not approved or intended for human use.
Research & Bioactivity
Researchers have studied PTD-DBM primarily in the context of Wnt/β-catenin signaling, a pathway involved in skin biology, hair follicle regulation, and wound healing processes. The peptide is designed to interfere with the interaction between CXXC5, a negative regulator of this pathway, and its binding partner Dishevelled, with studies investigating whether disrupting this interaction can modulate downstream signaling activity. In vitro and animal model studies have examined PTD-DBM in relation to hair follicle biology, including its potential role in androgenetic alopecia models where CXXC5 has been identified as a mediator of hair loss induced by prostaglandin D and dihydrotestosterone. Research has also investigated this peptide in the context of cutaneous wound healing, with studies exploring how Wnt/β-catenin pathway modulation may influence the wound repair microenvironment in preclinical models. Additional research has examined its incorporation into delivery systems such as adhesive hydrogel patches to study its effects on regenerative wound healing parameters in animal models. All published research involving PTD-DBM has been conducted under laboratory or preclinical conditions, and it is intended solely for research purposes.
Published Research
Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies.
Mehta A, Motavaf M, Raza D, McLure AJ, Osei-Opare KD, et al. — 2025
With alopecia affecting millions globally, recent advancements in the understanding of hair follicle biology have driven the development of novel therapies focused on hair regrowth. This review discusses two emerging therapeutic strategies: hair follicle neogenesis and the modulation of the Wnt/B-catenin signaling pathway. Hair follicle neogenesis, a frontier once considered impossible to achieve in adult humans, has recently gained traction due to advancements in stem cell biology and further understanding of the epithelial-mesenchymal interactions that are critical to hair follicle development. Such an approach shows significant potential for addressing conditions leading to hair loss, such as androgenetic and scarring alopecias. The Wnt/B-catenin signaling pathway, a critical intracellular pathway responsible for hair follicle cycles, has gained traction as a target for therapeutic interventions. Studies show that stimulating this pathway leads to hair follicle growth, while its inhibition prompts hair follicle regression. Investigations demonstrate clinical efficacy of small molecule inhibitors and peptides, such as PTD-DBM, which activates the Wnt/β-catenin pathway by interfering with CXXC5, a negative regulator that inhibits pathway activation. Such therapies show potential as more effective treatment options than existing solutions such as finasteride and minoxidil. Adjunctive therapies, such as low-level laser therapy, have also shown clinical efficacy, further highlighting how modulation of this pathway stimulates follicular regrowth. While these novel therapies require further research to validate their efficacy and to gain additional insight into their risk profile, it is clear that alopecia treatment is approaching a new frontier beyond traditional pharmacologic interviews, with regenerative medicine and pathway modulation paving the way forward.
Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment.
Lee SH, An S, Ryu YC, Seo SH, Park S, et al. — 2023
Regenerative wound healing involves the scarless wound healing as observed in fetal skin. Multiple features of regenerative wound healing have been well studied; however, the practical application of pro-regenerative materials to recapitulate the regenerative wound healing in adult skins has not yet been achieved. In this study, the authors identified that their novel pro-regenerative material, pyrogallol-functionalized hyaluronic acid (HA-PG) patches in combination with protein transduction domain-fused Dishevelled (Dvl)-binding motif (PTD-DBM), a peptide inhibiting the CXXC-type zinc finger protein 5 (CXXC5)-Dvl interaction, promoted regenerative wound healing in mice. The HA-PG patches loaded with this competitor peptide and valproic acid (VPA), a glycogen synthase kinase 3β (GSK3β) inhibitor, significantly inhibited scar formation during wound healing. The HA-PG patches with PTD-DBM and/or VPA inhibit the expression of differentiated cell markers such as α-smooth muscle actin (α-SMA) while inducing the expression of stem cell markers such as CD105 and Nestin. Moreover, Collagen III, an important factor for regenerative healing, is critically induced by the HA-PG patches with PTD-DBM and/or VPA, as also seen in VPA-treated Cxxc5 mouse fibroblasts. Overall, these findings suggest that the novel regeneration-promoting material can be utilized as a potential therapeutic agent to promote both wound healing and scar attenuation.
CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD.
Ryu YC, Park J, Kim YR, Choi S, Kim GU, et al. — 2023
The number of people suffering from hair loss is increasing, and hair loss occurs not only in older men but also in women and young people. Prostaglandin D (PGD) is a well-known alopecia inducer. However, the mechanism by which PGD induces alopecia is poorly understood. In this study, we characterized CXXC5, a negative regulator of the Wnt/β-catenin pathway, as a mediator for hair loss by PGD. The hair loss by PGD was restored by knock-out or treatment of protein transduction domain-Dishevelled binding motif (PTD-DBM), a peptide activating the Wnt/β-catenin pathway via interference with the Dishevelled (Dvl) binding function of CXXC5. In addition, suppression of neogenic hair growth by PGD was also overcome by PTD-DBM treatment or knock-out as shown by the wound-induced hair neogenesis (WIHN) model. Moreover, we found that CXXC5 also mediates DHT-induced hair loss via PGD. DHT-induced hair loss was alleviated by inhibition of both GSK-3β and CXXC5 functions. Overall, CXXC5 mediates the hair loss by the DHT-PGD axis through suppression of Wnt/β-catenin signaling.
The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing.
Lee SH, Kim MY, Kim HY, Lee YM, Kim H, et al. — 2015
Wnt/β-catenin signaling plays important roles in cutaneous wound healing and dermal fibrosis. However, its regulatory mechanism has not been fully elucidated, and a commercially available wound-healing agent targeting this pathway is desirable but currently unavailable. We found that CXXC-type zinc finger protein 5 (CXXC5) serves as a negative feedback regulator of the Wnt/β-catenin pathway by interacting with the Dishevelled (Dvl) protein. In humans, CXXC5 protein levels were reduced in epidermal keratinocytes and dermal fibroblasts of acute wounds. A differential regulation of β-catenin, α-smooth muscle actin (α-SMA), and collagen I by overexpression and silencing of CXXC5 in vitro indicated a critical role for this factor in myofibroblast differentiation and collagen production. In addition, CXXC5(-/-) mice exhibited accelerated cutaneous wound healing, as well as enhanced keratin 14 and collagen synthesis. Protein transduction domain (PTD)-Dvl-binding motif (DBM), a competitor peptide blocking CXXC5-Dvl interactions, disrupted this negative feedback loop and activated β-catenin and collagen production in vitro. Co-treatment of skin wounds with PTD-DBM and valproic acid (VPA), a glycogen synthase kinase 3β (GSK3β) inhibitor which activates the Wnt/β-catenin pathway, synergistically accelerated cutaneous wound healing in mice. Together, these data suggest that CXXC5 would represent a potential target for future therapies aimed at improving wound healing.